Roche’s Genentech is ending a partnership with Nykode Therapeutics that centered around a clinical-stage cancer vaccine ...

Key regulatory milestones and financial updates position Sangamo Therapeutics Inc (SGMO) for potential growth despite funding ...

RICHMOND, Calif., November 12, 2024 -- ( BUSINESS WIRE )--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today reported business highlights and third quarter 2024 financial ...

primarily due to their Genentech agreement, leading to a net income of $10.7 million compared to a loss in the previous year. Strategic developments include the submission of an IND application for a ...

A slow launch for Alzheimer's medicine Leqembi, a lackluster pipeline and a challenging drug launch environment are just a ...

Me is laying off 40% of its workforce, or more than 200 employees, and discontinuing its therapeutics division as the ...

and is coming up to a two-decade anniversary at the Roche/Genentech group. She also took control of the company during Hardy’s recent sabbatical, a longstanding policy at the biotech unit that ...

"I am thrilled to further strengthen and enrich Ocular's senior leadership team with the appointment of Namrata as Chief ...

At the heart of the alliance is the ‘lab-in-the-loop’ concept pioneered at Genentech’s Prescient Design accelerator unit. In a nutshell, that involves drawing on the company’s rich source ...

Founded more than 40 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and ...